Nuometa Completes Nearly RMB 100 Million Series A+ Financing Led by Oriza Holdings to Advance Metabolomics Research and Clinical Innovation, WinX Capital as Exclusive Financial Advisor

June 2023,Suzhou Panomics Biomedical Technology Co., Ltd. (hereinafter referred to as “Nuomi Metabolism”) announced the completion of its nearly RMB 100 million Series A+ financing round. The round was led by Yuanhe Holdings, with Junling Venture Capital participating as a co-investor. Existing shareholder Yuansheng Venture Capital continued to increase its investment, while Kaicheng Capital served as the exclusive financial advisor.The funds raised in this round of financing will be primarily used to accelerate the development of the single-cell multi-omics technology platform and expand the layout of specialized clinical product lines, thereby advancing research on cutting-edge metabolomics technologies and the development of innovative clinical applications.

Founded in 2013, Nuomi Metabolism is one of the earliest established and largest metabolomics companies in China. As a leader in the fields of life sciences and healthcare, it focuses on cutting-edge research in metabolomics technologies and the development of clinical applications. The company has built an integrated platform spanning metabolomics, clinical products, and big data analytics. Its business portfolio covers scientific research services, industrial services, new drug development services, clinical laboratory testing services, clinical products, and health management. Committed to becoming a comprehensive provider of precision medicine and precision nutrition solutions based on metabolomics, Nuomi Metabolism aims to serve as everyone’s personal metabolic health manager.

Leveraging continuous R&D accumulation and technological innovation, the company has developed multiple metabolomics-specific technologies and applied research achievements at an internationally advanced level. It offers over 100 testing and analysis services and more than 20 clinical diagnostic products, while maintaining several innovative product development pipelines covering diagnosis, early screening, and medication guidance in the fields of cardiovascular disease, stroke, oncology, and gut microbiota. During this period, the company was recognized as a leading technology enterprise and a high-tech enterprise, obtained ISO 9001 certification, CMA accreditation, and medical laboratory qualifications, thereby evolving into an industry leader.

Driven by the extensive and urgent clinical demands, clinical mass spectrometry in China has witnessed rapid development in recent years. Situated downstream of gene regulation and protein interaction networks, metabolomics filters out genetic and protein "noise" to provide comprehensive biological endpoint information. By leveraging the technical advantages of mass spectrometry—high sensitivity, high resolution, and high throughput—it offers more precise and personalized diagnostic and therapeutic evidence for clinical practice. In 2022, Nuomi Metabolism established a full-process service platform for clinical mass spectrometry. Guided by clinical research and supported by innovative clinical products, the company has strategically expanded into the life sciences and healthcare sectors, broadening its product coverage and continuously advancing the empowerment of precision medicine through metabolomics.

Mr. Ren Jianhong, Founder of Nuomi MetabolismStatement: We extend our gratitude to Yuanhe Holdings, Lingjun Venture Capital, and Yuansheng Venture Capital for their recognition and strategic support of the company. Amidst the booming trend in metabolomics, we continuously develop and optimize metabolomics technologies. Driven by frontier scientific research and supported by clinical needs, we have comprehensively established a differentiated portfolio of clinical diagnostic products. To date, Nuomi Metabolism has built a development system encompassing foundational technologies, scientific service products, medical translation, and clinically registered products. Moving forward, we will remain focused on breakthroughs in innovative technologies, application-oriented product development, and the commercialization of research outcomes, delivering higher-quality services and products to the market.

Project Leader, Yuanhe HoldingsStatement: As life sciences transition from the genomics era to the post-genomics era, metabolomics reveals the regulatory mechanisms of biological activities and metabolic pathways. It serves as an effective tool for life science research and the study of chronic diseases such as obesity, diabetes, cardiovascular and cerebrovascular disorders, and cancer, with promising potential in guiding disease prevention and treatment. Driven by robust demand for related scientific research and technical services, the market is rapidly emerging. As a top-tier enterprise in the field, Nuomi Metabolism boasts industry-leading comprehensive technical capabilities and has accumulated extensive market channel resources. The company is strategically positioned in both omics technical services and clinical applications, aiming to establish a dual-engine drive combining technical services with clinical application translation, thereby becoming a full-solution provider for metabolomics and clinical mass spectrometry.

Ms. Tao Shanshan, Head of Investment Department I at Lingjun Venture CapitalIt was stated that Nuomi Metabolism has built an integrated technology platform spanning metabolomics, clinical products, and big data analytics. With a focus on precision diagnosis and treatment as well as precision nutrition, the company provides personalized health assessments to the general public, holding significant clinical value and substantial market potential. Leading Venture Capital highly recognizes the company’s pioneering untargeted metabolomics technology and its comprehensive experimental system, which fully addresses end-user needs and lays a solid foundation for the clinical application of metabolic biomarkers. The collaboration with Nuomi Metabolism will further enhance the pharmaceutical ecosystem in Suzhou Industrial Park and boost regional innovation capabilities.

YuanDr. Lin Yi, Managing Partner at Shengchuang CapitalStatement: The field of metabolomics holds broad prospects. As a crucial component of systems biology, it complements the fundamental research methodologies in life sciences and has extensive applications in clinical medicine. Yuansheng Venture Capital remains bullish on Nuomi Metabolism’s team and its screening-to-translation model bridging scientific research and clinical practice. The company’s rapid growth has demonstrated its strong execution capabilities and commercialization prowess. We look forward to Nuomi’s differentiated clinical product portfolio unlocking the blue-ocean market of metabolic health within the broader wellness industry.

Dr. Zou Guowen, Founding Partner of Kaicheng CapitalStatement: Nuomi Metabolomics is a benchmark enterprise with significant growth potential in the field of metabolomics. Kaicheng Capital is honored to have supported the company in completing its Series A+ financing round. The company boasts a well-rounded team, and its founding members’ profound understanding of industry development trends has enabled them to proactively define the company’s future strategic direction and commercial layout. We are confident that, with the support of its shareholders, Nuomi Metabolomics will be further empowered to lead the life sciences sector toward deeper advancements in multi-omics.

Since its establishment in 2001, Yuanhe Holdings has focused on the field of equity investment, with assets under management exceeding RMB 100 billion, making it one of China’s leading equity investment firms. Since its inception, the company has prioritized investment opportunities in emerging industries such as integrated circuits, biopharmaceuticals, artificial intelligence, and nanotechnology applications, adhering to its commitment to supporting the real economy and promoting industrial transformation and upgrading. To date, it has directly invested in over 1,250 projects, while its fund-of-funds platform has invested in more than 150 subsidiary funds.

Leading Venture Capital was established in December 2012 as a wholly-owned subsidiary of the Suzhou Industrial Park Enterprise Development Service Center, with a registered capital of RMB 367.5 million. Its managed funds include the Park Science and Technology Innovation Fund and the Leading Yuanrui Fintech Fund, among others, with total assets under management amounting to RMB 2 billion. As the largest policy-oriented angel investment institution in Suzhou Industrial Park, it has played an active role in supporting the park’s efforts to attract high-end talent, accelerate corporate growth, and foster a technological innovation ecosystem.

YuanSheng Venture Capital is an investment firm focused on early- and growth-stage healthcare companies, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 170 outstanding life sciences and healthcare enterprises, spanning four key sectors: novel drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, and healthcare services. The firm has achieved substantial investment returns, with 19 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanSheng Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a world-class team of scientific advisors, YuanSheng Venture Capital leverages extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Guided by professionalism, focus, and rich industry resources, we are committed to becoming one of the most successful healthcare venture capital funds in China.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including “No. 1 Financial Advisor in Healthcare for 2022” by First New Voice, Tianyancha, and IT Juzi; “Top 2 Best Financial Advisors in Healthcare for 2021–2022” by Qimingpian and New Voice Innovation Services; and “Top 5 Healthcare Financial Advisors of the Year” at VCBeat’s 2022 Pengcheng Awards.